Taiho Oncology, Inc.

This study is testing whether adding an experimental drug called futibatinib to standard immunotherapy and chemotherapy can better control advanced esophageal or pancreatic cancer. It is for adults who have not yet received treatment for their advanced cancer. The goal is to see …

This early-stage trial tested whether adding a new drug called tolinapant to an existing oral lymphoma treatment (decitabine/cedazuridine) was safe and effective for people with relapsed T-cell lymphoma. The study aimed to find the right dose and see if the combination could shri…

This study is testing a combination of two oral drugs, ASTX727 and venetoclax, for adults newly diagnosed with acute myeloid leukemia (AML) who are age 75 or older, or who have other health problems that make them unable to receive standard intensive chemotherapy. The main goals …

This study allows cancer patients who were already receiving futibatinib in a previous Taiho-sponsored trial to continue taking the medication if they're benefiting from it. The main purpose is to monitor the long-term safety of continued futibatinib treatment. Only patients who …

This study allows patients with certain blood cancers who were benefiting from ASTX727 treatment in previous trials to continue receiving the medication. The main goal is to collect long-term safety information about the drug. Participants will receive the same dose they were tak…

This study is testing if adding a new drug called zipalertinib to standard chemotherapy works better than chemotherapy alone for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the combination can …

This study is testing a new oral drug called ASTX660 in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to see if the drug can help control the cancer. The trial i…

This program provides access to the drug futibatinib for patients with advanced bile duct cancer who have a specific genetic change (FGFR2 rearrangement) and whose standard treatments have stopped working or caused too many side effects. The drug is already approved for marketing…